Filter Results

Clinical Studies


Closed for Enrollment

  • A Feasibility Pilot Comparing a Non-invasive Low Level Laser Therapy (LLLT) With Lorcaserin to Reduce Central Adiposity in Overweight Individuals Rochester, Minn. Currently in the United States about 97 million adults are considered obese, accounting for about 33% of the American adult population (compared to 22.9% in 1988). Obesity, defined as a body mass index of 30.0 or higher, is accountable for 44% of the diabetes, 23% of the ischemic heart disease and between 7% and 41% of certain cancers. The Erchonia® Zerona™ 2.0 Laser (which will be used in this study) has been approved by the FDA (K123237) as a non-invasive dermatological aesthetic treatment which can be used by individuals intending to reduce circumference of hips, waist, and thighs. Lorcaserin is a selective serotonin 2C (5-HT(2C)) receptor agonist. The exact mechanism of action is not known, but lorcaserin is believed to promote satiety and decrease food intake by activating 5-HT(2C) receptors on anorexigenic pro-opiomelanocortin neurons in the hypothalamus. Lorcaserin was approved by the FDA on June 2012 for weight management in people with a BMI of > 27 kg/m2 (overweight) when accompanied by a weigh-related condition such as type 2 diabetes or high blood pressure or in people with a BMI > 30 kg/m2 (obese). The purpose of this pilot study is to obtain preliminary data on: 1) effectiveness of the combination of LLLT and lorcaserin for reducing abdominal subcutaneous fat in overweight/obese individuals; 2) impact of LLLT on inflammatory biomarkers, blood sugar, and cholesterol.
  • A Feasibility Study Evaluating Mindfulness-Based Intervention Assessing A Wearable Wellness Brain Sensing Device (Muse-S™) in Practicing Health Care Providers (Muse-S) Rochester, Minn.

    A study to asses the feasibility of health care providers using a wearable brain sensing wellness device (Muse-S™) during a time of increased work load, patient volume and stressors.  Also determine the association between duration of active state and calm state as measured by the wearable brain sensing wellness device (Muse-S™) and quality of life (QOL), subjective stress, sleep and resilience.

  • Acceptability of Virtual Reality Experience by Health Care Providers for Improving Focus and Reducing Anxiety: A Pilot Trial (R-VR) Rochester, Minn.

    The purpose of this study is to evaluate using the Reulay Virtual Reality (R-VR) to help reduce anxiety and burnout symptoms and improve focus by combining nature-based interventions with virtual reality (VR) to decrease anxiety in the workplace.

  • First Responder Resiliency Program for Health Care Professionals During a Pandemic Rochester, Minn.

    The purpose of this study is to evaluate the feasibility of a resiliency program to provide an effective and sustainable solution to several important problems experienced by medical professionals.

  • Varenicline for Light Smokers (ChanLight) Rochester, Minn.

    The purpose of this study is to determine if varenicline is effective in treating tobacco dependence in adults who smoke 5-10 cigarettes per day.